Search company, investor...

Predict your next investment

Corporate Venture
novoholdings.dk/investments/ventures

Investments

160

Portfolio Exits

62

Funds

2

Service Providers

2

About Novo Ventures

Novo Ventures, part of Novo Holdings, is a life science venture capital investor, delivering knowledge, network, and capital to companies. The firm strives to invest in companies that develop innovative drugs, medical devices and diagnostics that can potentially improve the health and welfare of people around the world.

Headquarters Location

501 2nd Street Suite 300

San Francisco, California, 94107,

United States

+1 (415) 552-6686

Want to inform investors similar to Novo Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Novo Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Novo Ventures in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Novo Ventures News

Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Developmen...

Jan 6, 2023

Venture Capital News | Private Equity News venture capital directory | private equity directory Venture Capital Firms List / Venture Capital & Private Equity Firms and Sources Published since 1998, VCPro Database is the most reliable, up-to-date and affordable venture capital directory 2022 Newly Updated Edition Now Available! (Updated JULY 2022) VCPro Database 2022 25th Edition — a downloadable and searchable venture capital database with 6,800+ venture capital and private equity firms worldwide. The most reliable, up-to-date and affordable venture capital directory of its kind. VCPro Database is available in both Windows and macOS versions. It has been published since 1998. Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline • $100M Series B extension financing co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors, including Leaps by Bayer and Moderna, as well as the initial Series B leads PFM Health Sciences, Farallon Capital Management, and a leading global investment firm • Extension of cash runway solidifies Metagenomi’s leadership position within the next-generation gene editing field, enabling advancement of Metagenomi’s lead therapeutic programs into clinical studies, and expansion of its genetic medicines pipeline, powered by the largest proprietary next-generation gene editing platform • Ray Camahort, Ph.D., Partner at Novo Ventures, a wholly owned subsidiary of Novo Holdings, to join Metagenomi’s board as an observer EMERYVILLE, Calif., January 5, 2023-- Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the close of a Series B extension financing, co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors. This $100M financing brings the total Series B proceeds to $275M, with over 30 investment groups participating. In connection with the financing, Ray Camahort, Ph.D., Partner at Novo Ventures, will join Metagenomi’s board as an observer. “At Novo Holdings, our purpose is to improve people’s health and the sustainability of society and the planet. Metagenomi continues to display an impressive track record of rapidly developing novel gene editing systems and advancing them through preclinical validation,” said Ray Camahort Ph.D., Partner at Novo Ventures. “With the combination of Metagenomi’s next-generation technology platform, preclinical progress, numerous validating partnerships and strong investors, we believe the Company is well positioned to rapidly develop therapeutics to treat a broad range of genetic diseases.” With a healthy cash runway off the heels of successful partnerships with Moderna and Ionis Pharmaceuticals, this additional capital will enable Metagenomi to advance its lead therapeutic programs through preclinical development and into clinical proof-of-concept. Furthermore, the Company plans to nominate additional therapeutic targets to its proprietary genetic medicines pipeline, fueled by its automated discovery engine and versatile gene editing toolbox, to expand into additional preclinical proof-of-concept studies. “The closing of this Series B extension financing is a testament to our significant progress over the past year. We further expanded our toolbox of wholly owned, next-generation gene editing technologies, embarked on our first nonhuman primate (NHP) in vivo gene editing proof-of-concept studies and strengthened our strategic business development alliances,” said Brian C. Thomas, CEO and Founder of Metagenomi. “This additional capital gives us visibility on initial clinical milestones as well as an expanded pipeline of in vivo gene editing applications.” About Metagenomi Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co About Novo Holdings Novo Holdings is a holding and investment company that is responsible for managing the assets of the Novo Nordisk Foundation, one of the world’s largest enterprise foundations. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes (the Novo Group companies) and manages an investment portfolio, with a long-term return perspective. Novo Holdings invests in life science companies of all stages of development and also manages a broad portfolio of equities, bonds, real estate and infrastructure assets as well as private equity investments. As of year-end 2021, Novo Holdings had total assets of USD 106 billion. Further information: www.novoholdings.dk About Catalio Capital Management Catalio Capital Management, LP, is a multi-strategy life sciences investment firm that focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics, and data-driven insights. The firm currently manages over $1 billion assets across its private equity, private credit, and public equities strategies. Catalio's Partnership includes over 39 world-renowned scientists with extensive academic and scientific achievements who have each started well-established companies based on their research. Catalio has offices in New York, Baltimore, and London. About SymBiosis SymBiosis is an investment firm focused on advancing biotherapeutics innovations for serious and life-threatening diseases. The firm invests in groundbreaking medicines across disease areas, financing stage, and geography, with a focus on programs in, or about to enter, human trials. SymBiosis currently manages a portfolio of more than 30 investments and has significant, long-term capital commitments to fund future investments. For more information, please visit www.symbiosis.vc Contact:

Novo Ventures Investments

160 Investments

Novo Ventures has made 160 investments. Their latest investment was in MapLight Therapeutics as part of their Series B - II on November 11, 2022.

CBI Logo

Novo Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/10/2022

Series B - II

MapLight Therapeutics

$12M

Yes

1

8/4/2022

Unattributed VC - VI

F2G

$70M

No

4

9/8/2021

Series D

InBrace

$102M

No

15

5/20/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

4/9/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/10/2022

8/4/2022

9/8/2021

5/20/2021

4/9/2021

Round

Series B - II

Unattributed VC - VI

Series D

Series C

Series C

Company

MapLight Therapeutics

F2G

InBrace

Subscribe to see more

Subscribe to see more

Amount

$12M

$70M

$102M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

4

15

10

10

Novo Ventures Portfolio Exits

62 Portfolio Exits

Novo Ventures has 62 portfolio exits. Their latest portfolio exit was SeaSpine on January 10, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/10/2023

Take Private

$99M

3

11/22/2022

Acq - P2P

$99M

4

4/7/2022

Acquired

$99M

9

2/4/2022

IPO

Subscribe to see more

$99M

Subscribe to see more

10

11/22/2021

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/10/2023

11/22/2022

4/7/2022

2/4/2022

11/22/2021

Exit

Take Private

Acq - P2P

Acquired

IPO

Acq - P2P

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

4

9

10

10

Novo Ventures Fund History

2 Fund Histories

Novo Ventures has 2 funds, including Novo Seed.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Novo Seed

Early-Stage Venture Capital

Unknown

1

REPAIR Impact Fund

Subscribe to see more

Subscribe to see more

10

Closing Date

Fund

Novo Seed

REPAIR Impact Fund

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Unknown

Subscribe to see more

Amount

Sources

1

10

Novo Ventures Service Providers

2 Service Providers

Novo Ventures has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Provider Type

Counsel

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Partnership data by VentureSource

Novo Ventures Team

8 Team Members

Novo Ventures has 8 team members, including current Senior Partner, Stephan Christgau.

Name

Work History

Title

Status

Stephan Christgau

Osteologix, Nordic Bioscience, and Novo Nordisk

Senior Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Stephan Christgau

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Osteologix, Nordic Bioscience, and Novo Nordisk

Title

Senior Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.